Clinical Importance of Blood Drug Concentration of Oral Molecular Targeted Drugs for Renal Cell Carcinoma

被引:0
作者
Takasaki, Shinya [1 ]
Kawasaki, Yoshihide [2 ]
Kikuchi, Masafumi [1 ]
Ito, Akihiro [2 ]
Yamaguchi, Hiroaki [1 ]
Mano, Nariyasu [1 ]
机构
[1] Tohoku Univ Hosp, Dept Pharmaceut Sci, Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan
[2] Tohoku Univ Hosp, Dept Urol, Aoba Ku, Sendai, Miyagi, Japan
关键词
TYROSINE KINASE INHIBITOR; IMATINIB PHARMACOKINETICS; INDUCED TOXICITIES; ANTITUMOR-ACTIVITY; JAPANESE PATIENTS; N-OXIDE; SUNITINIB; EVEROLIMUS; SAFETY; SORAFENIB;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose: Therapeutic drug monitoring (TDM) is widely used in clinical practice to maximize drug efficacy and minimize toxicities. Currently, it is also practiced in the use of oral molecular targeted drugs. The objective of this study was to assess the clinical importance of measuring the systemic concentration of oral molecular targeted drugs used to treat renal cell carcinoma (RCC). Methods: The systemic concentrations of the oral molecular targeted drugs sorafenib, sunitinib, axitinib, pazopanib, and everolimus used for RCC were useful for therapeutic interventions, and clinical outcomes were evaluated retrospectively. Results: The interventional use of systemic drug concentration was confirmed in 26 of 87, and their categories are presented. The systemic concentration of sunitinib was useful in dose reduction and/or discontinuation (n = 10), dose escalation (n = 3), and adherence monitoring (n = 2). Nine of the 10 patients whose dose was reduced showed reduced adverse event. Two patients who were intervened in adherence monitor showed improved adherence. For axitinib, dose reduction and/or discontinuation (n = 1) and dose escalation (n = 6) were confirmed. For pazopanib, dose reduction and/or discontinuation (n = 1) and drug interaction detection (n = 1) were confirmed, both of them were confirmed to have reduced adverse events. For everolimus, dose reduction and/or discontinuation (n = 1) and drug interaction detection (n = 1) were confirmed, a patient with reduced dose recovered from adverse events. Interventions for sorafenib were not identified. Conclusions: This study demonstrated that systemic concentrations of oral molecular targeted drugs for RCC were considered to be clinically useful for dose adjustment, monitoring of treatment adherence, and the detection of drug interactions. Moreover, this information could be successfully used to guide individualized therapy to maximize the antitumor effects of these
引用
收藏
页码:127 / 136
页数:10
相关论文
共 49 条
[1]   Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors [J].
Adams, Val R. ;
Leggas, Markos .
CLINICAL THERAPEUTICS, 2007, 29 (07) :1338-1353
[2]   Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma [J].
Choueiri, T. K. ;
Escudier, B. ;
Powles, T. ;
Mainwaring, P. N. ;
Rini, B. I. ;
Donskov, F. ;
Hammers, H. ;
Hutson, T. E. ;
Lee, J-L ;
Peltola, K. ;
Roth, B. J. ;
Bjarnason, G. A. ;
Geczi, L. ;
Keam, B. ;
Maroto, P. ;
Heng, D. Y. C. ;
Schmidinger, M. ;
Kantoff, P. W. ;
Borgman-Hagey, A. ;
Hessel, C. ;
Scheffold, C. ;
Schwab, G. M. ;
Tannir, N. M. ;
Motzer, R. J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (19) :1814-1823
[3]   Benefit of therapeutic drug monitoring to disclose pharmacokinetic interaction between sunitinib and calcium channel blocker [J].
Da Silva, F. ;
Thomas-Schoemann, A. ;
Huillard, O. ;
Goldwasser, F. ;
Blanchet, B. .
ANNALS OF ONCOLOGY, 2016, 27 (08) :1651-1652
[4]   CYP3A5 and ABCB1 Polymorphisms as Predictors for Sunitinib Outcome in Metastatic Renal Cell Carcinoma [J].
Diekstra, Meta H. M. ;
Swen, Jesse J. ;
Boven, Epie ;
Castellano, Daniel ;
Gelderblom, Hans ;
Mathijssen, Ron H. J. ;
Rodriguez-Antona, Cristina ;
Garcia-Donas, Jesus ;
Rini, Brian I. ;
Guchelaar, Henk-Jan .
EUROPEAN UROLOGY, 2015, 68 (04) :621-629
[5]   Sorafenib in advanced clear-cell renal-cell carcinoma [J].
Escudier, Bernard ;
Eisen, Tim ;
Stadler, Walter M. ;
Szczylik, Cezary ;
Oudard, Stephane ;
Siebels, Michael ;
Negrier, Sylvie ;
Chevreau, Christine ;
Solska, Ewa ;
Desai, Apurva A. ;
Rolland, Frederic ;
Demkow, Tomasz ;
Hutson, Thomas E. ;
Gore, Martin ;
Freeman, Scott ;
Schwartz, Brian ;
Shan, Minghua ;
Simantov, Ronit ;
Bukowski, Ronald M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :125-134
[6]   Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia [J].
Evans, WE ;
Relling, MV ;
Rodman, JH ;
Crom, WR ;
Boyett, JM ;
Pui, CH .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (08) :499-505
[7]   Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer [J].
Faivre, S ;
Delbaldo, C ;
Vera, K ;
Robert, C ;
Lozahic, S ;
Lassau, N ;
Bello, C ;
Deprimo, S ;
Brega, A ;
Massimini, G ;
Armand, JP ;
Scigalla, P ;
Raymond, E .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (01) :25-35
[8]   Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial [J].
Franz, David Neal ;
Belousova, Elena ;
Sparagana, Steven ;
Bebin, E. Martina ;
Frost, Michael ;
Kuperman, Rachel ;
Witt, Olaf ;
Kohrman, Michael H. ;
Flamini, J. Robert ;
Wu, Joyce Y. ;
Curatolo, Paolo ;
de Vries, Petrus J. ;
Whittemore, Vicky H. ;
Thiele, Elizabeth A. ;
Ford, James P. ;
Shah, Gaurav ;
Cauwel, Helene ;
Lebwohl, David ;
Sahmoud, Tarek ;
Jozwiak, Sergiusz .
LANCET, 2013, 381 (9861) :125-132
[9]   Exposure-Toxicity Relationship of Sorafenib in Japanese Patients with Renal Cell Carcinoma and Hepatocellular Carcinoma [J].
Fukudo, Masahide ;
Ito, Takuma ;
Mizuno, Tomoyuki ;
Shinsako, Keiko ;
Hatano, Etsuro ;
Uemoto, Shinji ;
Kamba, Tomomi ;
Yamasaki, Toshinari ;
Ogawa, Osamu ;
Seno, Hiroshi ;
Chiba, Tsutomu ;
Matsubara, Kazuo .
CLINICAL PHARMACOKINETICS, 2014, 53 (02) :185-196
[10]   Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: Results of a multicenter randomized trial of patients with metastatic colorectal cancer [J].
Gamelin, Erick ;
Delva, Remy ;
Jacob, Jacques ;
Merrouche, Yacine ;
Raoul, Jean Luc ;
Pezet, Denis ;
Dorval, Etienne ;
Piot, Gilles ;
Morel, Alain ;
Boisdron-Celle, Michele .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (13) :2099-2105